Skip to content
Search

Latest Stories

Reflections on my first year as Numark UK chairman

Harry McQuillan reflects on his first year as chairman of Numark UK
Harry McQuillan, Numark UK Chairman

The lack of a stable, predictable funding framework remains a critical issue for pharmacies in England - Harry McQuillan

As I reflect on my first year as chairman of Numark, I am struck by the incredible progress we’ve made together and the exciting opportunities that lie ahead for community pharmacy. This milestone feels like the perfect moment to take stock of our achievements and look forward to the future.

Stepping into this role after 17 years as a chief executive was both exhilarating and, I’ll admit, a little daunting. However, any initial apprehension quickly faded thanks to the warm welcome and support from my fellow UK Board members, the exceptional Numark team, and our dedicated members. It’s this shared sense of purpose, supporting our members to deliver outstanding care to their communities that continues to inspire me every day.


One of my first priorities was to clearly define what Numark stands for. Together, we established a mission that reflects our commitment: “Numark is the support organisation to more than 5500 community pharmacies, dedicated to enhancing their business performance and the delivery of safe effective pharmaceutical care. We maximise our scale to add value to our pharmacy partners.”

This mission is far more than just words on paper, it’s a promise that guides everything we do. From providing practical support to advocating for the future of community pharmacy, it shapes our actions and priorities.

A defining moment of the past year was the launch of our 12 Principles for the Future Model of Community Pharmacy Practice. This initiative marked a significant step forward, sparking vital conversations about how pharmacy can evolve to meet the changing needs of patients and the NHS. I’m proud to share that the chief pharmaceutical officers from all four UK nations engaged with our vision, recognising its importance and relevance.

Yet, no vision for the future can succeed without proper funding. The lack of a stable, predictable funding framework remains a critical issue, particularly for pharmacies in England. Addressing this challenge is a top priority, and I am committed to working closely with contractor negotiating bodies to secure the financial stability our sector needs to thrive.

This year also saw the re-establishment of our country-specific advisory boards, providing members with a platform to share their insights and feedback. These sessions have already driven meaningful improvements, including enhancements to NumarkNet, updates to our training platform, and new initiatives set to launch later this year. Listening to our members and acting on their feedback is at the heart of what we do, and this collaborative approach will remain central to our work.

We’ve made significant strides in positioning Numark as a thought leader for the sector, but there’s still more to do. For me, it’s about ensuring that the incredible work our members do every day is not only recognised but celebrated. Community pharmacies are the backbone of countless communities, and I am determined to amplify their voices and champion their contributions.

Looking back on the past year, I feel immense pride in what we’ve achieved together. At the same time, I am more determined than ever to tackle the challenges ahead. Community pharmacy stands at a crossroads, and while the path forward may not always be easy, I am confident that by working together, we can secure the bright future our sector deserves.

To all community pharmacies across the UK, wherever you operate, I extend my heartfelt thanks for everything you do. Your dedication and resilience are an inspiration, and I look forward to continuing our partnership as we move into 2025 and beyond. Together, we will keep pushing boundaries, driving innovation, and ensuring community pharmacy remains at the heart of healthcare.

More For You

Why community pharmacy must embrace private services
The range of private services offered by pharmacists is likely to grow exponentially over the coming years (gettyimages)

Future of community pharmacy: Be more private

Tariq Muhammad considers how community pharmacy must explore private services to help create a more sustainable future.

We know remuneration influences behaviour. If I have a construction company and I pay a bricklayer a fee per brick to supply and fit, I suspect he will source them from the cheapest supplier and lay as many bricks as he possibly can. If one day, I reduce the fee such that it barely covers the cost of the brick, at a time when bricks are in short supply and labour costs have gone up, oh and I take some money off him for the profit he made on bricks he supplied the previous year, I suspect he will tell me to stick my job where the sun doesn’t shine.

It may be a crude analogy, but it is pretty much what’s happened in community pharmacy over the last 20 years. The remuneration we get for dispensing does not cover the cost of providing the service. The reimbursement for the drugs does not cover the cost of the drugs. In fact, we make a loss on many items given all the clawbacks and supply shortages. Wages have gone up. And then each year the government claws back profit they say we’ve made, apparently!

Keep ReadingShow less
Why community pharmacy must embrace private services
The range of private services offered by pharmacists is likely to grow exponentially over the coming years (gettyimages)

Future of community pharmacy: Be more private

Tariq Muhammad considers how community pharmacy must explore private services to help create a more sustainable future.

We know remuneration influences behaviour. If I have a construction company and I pay a bricklayer a fee per brick to supply and fit, I suspect he will source them from the cheapest supplier and lay as many bricks as he possibly can. If one day, I reduce the fee such that it barely covers the cost of the brick, at a time when bricks are in short supply and labour costs have gone up, oh and I take some money off him for the profit he made on bricks he supplied the previous year, I suspect he will tell me to stick my job where the sun doesn’t shine.

It may be a crude analogy, but it is pretty much what’s happened in community pharmacy over the last 20 years. The remuneration we get for dispensing does not cover the cost of providing the service. The reimbursement for the drugs does not cover the cost of the drugs. In fact, we make a loss on many items given all the clawbacks and supply shortages. Wages have gone up. And then each year the government claws back profit they say we’ve made, apparently!

Keep ReadingShow less
collaboration in healthcare settings
collaboration in healthcare settings

Do you have to like each other to Collaborate?

By Trevor Gore, Associate Director, Institute for Collaborative Working (ICW)

May I be one of the last people to wish you a ‘Happy New Year’

The new year is traditionally a time to reflect on the year past and look forward to the new year and all the joys and challenges it will bring, possibly by making a resolution. However, the statistics do not bode well for your resolution lasting.

Keep ReadingShow less
Ministers must now urgently table the long trailed new deal for community pharmacy
Paul Rees Former NPA chief executive

Community pharmacy owners are ‘fed up’ with how they’re treated by the NHS

"Ministers must now urgently table the long trailed new deal for community pharmacy"

By Paul Rees, former chief executive of the National Pharmacy Association (NPA)

When former Health Secretary Matt Hancock gave evidence to the Covid public inquiry he let the cat out of the bag.

Keep ReadingShow less
Category M price list for January 2025
gettyimages

Impact of Category M price changes in January 2025

Pharmacies face £1,100 monthly reimbursement cuts as government implements £34 million adjustment to Category M prices

The government have imposed a £34 million per quarter adjustment to the prices of Category M* products in the English Drug Tariff from January 2025. They say that this is to compensate for retained margin adjustment following the latest margin survey, changes in the current market prices of medicines, and the addition of new lines into this category.

Keep ReadingShow less